|Dr. Steven C. Quay||Chairman, CEO & Pres||919.59k||N/A||1951|
|Mr. Kyle Guse CPA, Esq., CPA||CFO, Gen. Counsel & Sec.||629.18k||N/A||1964|
|Ms. Janet Rose Rea||Sr. VP of Regulatory, Quality & Clinical Affairs||N/A||N/A||N/A|
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Atossa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.